Tsukada K, Nomura T, Higashi K, Takeuchi T
1st Department of Internal Medicine, Nagoya City University Medical School.
Nihon Rinsho. 1994 Jul;52(7):1895-900.
One hundred and twenty patients with chronic hepatitis C were treated with a 6-month course of recombinant alpha-interferon (a daily dose of 6 MU i.m. for the first two weeks and 6 MU or 3 MU i.m. three times weekly thereafter). Serum levels of thyroxine (T4), triiodothyronine (T3), thyroid-stimulating hormone (TSH), antithyroglobulin antibody (TGHA) and antimicrosomal antibody (MGHA) were measured before and three month after treatment. Ten of 106 patients with normal thyroid function test before therapy developed thyroid dysfunction; five with hyperthyroidism, four with hypothyroidism and one with positive MCHA. Fourteen patients had thyroid function disorder before treatment. Seven of eight patients with positive MCHA, showed a rise in the titer during the treatment. These data showed that a small proportion of patients treated with interferon developed thyroid dysfunction during the treatment. The interferon-induced thyroid dysfunction appears to be caused via the immune system but also by acting directly on the thyroid gland.
120例慢性丙型肝炎患者接受了为期6个月的重组α干扰素治疗（前两周每日肌肉注射6百万单位，此后每周三次，每次肌肉注射6百万单位或3百万单位）。在治疗前及治疗三个月后检测血清甲状腺素（T4）、三碘甲状腺原氨酸（T3）、促甲状腺激素（TSH）、抗甲状腺球蛋白抗体（TGHA）和抗微粒体抗体（MGHA）水平。治疗前甲状腺功能检查正常的106例患者中有10例出现甲状腺功能障碍；5例为甲状腺功能亢进，4例为甲状腺功能减退，1例MCHA阳性。14例患者在治疗前有甲状腺功能紊乱。8例MCHA阳性患者中有7例在治疗期间滴度升高。这些数据表明，一小部分接受干扰素治疗的患者在治疗期间出现甲状腺功能障碍。干扰素诱导的甲状腺功能障碍似乎是通过免疫系统引起的，但也可能是直接作用于甲状腺所致。
